Posted on

FDA OKs Istradefylline for Parkinson’s Disease ‘Off’ Episodes

Posted on

The US Food and Drug Administration (FDA) has approved istradefylline (Nourianz, Kyowa Kirin) tablets as add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease (PD) experiencing “off” episodes.

Istradefylline is a selective adenosine A2A receptor antagonist.

Its effectiveness in treating “off” episodes in patients with PD taking levodopa/carbidopa was shown in four 12-week, placebo-controlled clinical studies that included a total of 1143 participants.

In all four studies, addition of istradefylline led to a statistically significant decrease from baseline in daily “off” time relative to placebo add-on, the FDA said in a news release.

The most common adverse reactions observed in patients taking istradefylline were dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia. Patients should be monitored for development of dyskinesia or exacerbation of existing dyskinesia. If hallucinations, psychotic behavior, or impulsive/compulsive behavior occurs, consider reducing the dose or stopping the drug, the FDA advises.

Use of istradefylline in pregnancy is not recommended and women of childbearing potential should be advised to use contraception during treatment.

According to the National Institutes of Health, PD is the second most common neurodegenerative disorder in the United States after Alzheimer’s disease. An estimated 50,000 Americans are diagnosed with PD each year, and about 1 million Americans have the condition.

GDMeds, an India Pharmacy Service company
 [Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
[免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作,需遵守第三方的版权,特别是标示为第三方内容的。如用户发现侵犯版权的行为,请通知极得美。一旦收到违反通知,极得美将立刻移除相关内容。
[отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент.